European Pharmaceutical Review

SEPTEMBER 21, 2023

In this Q&A, Karen Pinachyan, Head of Medical Affairs Europe at CSL Behring summarises key considerations for gene therapy drug development and the ideal approach for alleviating economic strain when advancing these modern treatments. 4,5 What is the key consideration drug developers should apply to gene therapies?

Drug Development 96

Drug Development Pharmaceutical Companies Pharmaceutical Companies Diabetes 96

pharmaphorum

SEPTEMBER 29, 2020

The pharmaceutical industry is one of the most scientifically innovative and competitive industries, particularly in oncology. As of 2018, there were over 1,100 cancer therapies in development, and as of 2020, 362 of them were cell and gene therapies.

Drug Development 132

Drug Development Chemotherapy Pharmaceutical Companies Pharmaceutical Companies 132

European Pharmaceutical Review

AUGUST 17, 2022

The investigators found that the high burden of chronic and infectious diseases, growing focus on bioavailability enhancement for poorly soluble drugs, and the challenges associated with drug development were the major contributors to the demand for formulation development services globally.

Compounding 96

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Development 96

pharmaphorum

OCTOBER 7, 2020

SMi Reports: An exclusive interview with María José López Barragán, Founder, Barragan BioConsulting, formerly CMC Product Quality Reviewer, FDA, who will be speaking at the 3rd Annual Pharmaceutical Microbiology East Coast Conference released. SMi’s 3rd Annual Pharmaceutical Microbiology East Coast. Conference: October 28th-29th, 2020.

Biosimilars 52

Biosimilars Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

Pharmaceutical Technology

OCTOBER 26, 2022

Over recent years, many pharmaceutical companies have taken up environment, social and governance (ESG) targets in order to prioritize sustainability whilst boosting their external public relations. GlobalData is the parent company of Pharmaceutical Technology.

Pharmaceutical Companies 64

Pharmaceutical Companies Pharmaceutical Companies Hospitals Drug Development 64

pharmaphorum

OCTOBER 16, 2020

The repurposing of drugs is becoming more common, especially in the field of rare diseases. Now, as part of lifecycle management, pharmaceutical companies are looking more closely at drugs they have on their shelves. In the past, repurposing has mostly been driven by academics looking for new possibilities in generics.

Drug Development 105

Drug Development Immunity Immunization Pharmaceutical Companies 105

Pharmaceutical Technology

DECEMBER 9, 2022

Pharmaceutical sales in Brazil reached $17bn in 2021, according to GlobalData figures. Despite this, Brazil’s trade protectionist policies mean that there are few pharmaceutical companies of international origin within the country. Brazilian public spending on healthcare, drug pricing reforms and remote medicine.

Drug Pricing 98

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 98

European Pharmaceutical Review

JULY 4, 2024

4,6 Five patent issues that European biosimilar developers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi. BMB Reports. 2017;50(3):111–6. Premier Consulting [Internet].

Drug Development 103

Drug Development Biosimilars Documentation Labelling 103

European Pharmaceutical Review

DECEMBER 21, 2022

“As the contribution of costs of organic chemicals used as feedstock to the operating expenditures is small, the pharmaceutical companies can spearhead and guide the transition.” He is currently group leader of the Technology Development and Discovery Group at the Bioprocess Laboratory of the ETH.

Compounding 97

Compounding Pharmaceutical Manufacturing Pharmaceutical Companies Pharmaceutical Companies 97

European Pharmaceutical Review

SEPTEMBER 2, 2022

She has worked with regulatory agencies and pharmaceutical companies for over 10 years. US Food and Drug Administration. Patient-Focused Drug Development: Collecting Comprehensive and Representative Input Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders; June 2020.

Adverse Reactions 96

Adverse Reactions Documentation Medical Schools Packaging 96

PharmaState Academy

OCTOBER 20, 2023

a) 70% b) 40% c) 20% d) 10% 10 / 20 When was the FDA's Patient-Focused Drug Development (PFDD) initiative launched? a) 2012 b) 2000 c) 1990 d) 2020 11 / 20 What role does understanding patient journeys play in Pharma Marketing?

Dosage 59

Dosage Pharmaceutical Companies Pharmaceutical Companies Process Improvement 59

PharmaShots

APRIL 27, 2023

Multi-Country Safety Head – South Asia & Indo-China (Vietnam), Sanofi, India Naveen Chhabra, Global Medical Safety Lead, Global Drug Development, Novartis, India Varun Dua, Vice President -Professional Services, RxLogix, India Dhanaraj E, Pharmacovigilance Lead- CDMA-BBL, Biocon, India Kanchan Kanitkar, Sr. REGISTER NOW!

Drug Development 40

Drug Development Pharmaceutical Companies Pharmaceutical Companies 40

Pharmaceutical Technology

FEBRUARY 28, 2023

For many years, the pharmaceutical industry has been accused of overlooking this patient population by instead targeting investments toward more prevalent indications. Orphan drug development is expanding Change is happening. With similar incentives offered by EU/EEA and UK law, orphan drug development has taken off.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Drug Development Communication 52

pharmaphorum

MARCH 30, 2021

“There’s a lot that drug development for more common diseases could learn from rare disease R&D”. I think there’s a lot that drug development for more common diseases could learn from rare disease R&D.”. We have to be innovative to get around those challenges. Rare diseases during COVID.

Hospitals 111

Hospitals Communication Drug Development Pharmaceutical Companies 111

European Pharmaceutical Review

OCTOBER 19, 2022

Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment. 2020-02-24.

Biosimilars 96

Biosimilars Dosage Drug Pricing Pharmaceutical Companies 96

pharmaphorum

APRIL 11, 2022

Delivering value for patients doesn’t start and end in our R&D labs; actions can be implemented across all stages of the drug development lifecycle to encourage and embrace a pro-innovation environment. The role of innovation in value-based healthcare. About the author.

Pharmaceutical Companies 115

Pharmaceutical Companies Pharmaceutical Companies Vaccines Packaging 115

Pharmaceutical Technology

JULY 23, 2008

The world’s biggest pharmaceutical company Pfizer announced in June 2008 that it would be putting its “full scope and scale” behind a push into the cancer market. ” “Between 2003 and 2005 global sales for cancer-treating drugs grew by 40%.” “For certain cancers, yes,” says Ando.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Compounding Biosimilars 40

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Vaccines 116

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Development 116

pharmaphorum

SEPTEMBER 9, 2021

But when the pandemic struck in early 2020, we were found wanting. Surgical activity in England and Wales alone reduced by a third during 2020, a shortfall estimated to increase to 2.4 Mark Hicken is vice president of strategy for Europe, Middle East and Africa (EMEA) at Janssen, the Pharmaceutical Companies of Johnson & Johnson.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies Hospitals 52

European Pharmaceutical Review

FEBRUARY 1, 2024

What are the top three trends impacting the cardiovascular drug development space today? Beyond clinical trials, what other challenges are impacting pharmaceutical companies today? You see very few cardiovascular companies as a startup biotech, and there are reasons for that.

Documentation 97

Documentation Diabetes Pharmaceutical Companies Pharmaceutical Companies 97

pharmaphorum

OCTOBER 28, 2020

Data defines modern therapeutics, but this is almost uniquely confined to the clinical trial stages of drug development. Identifying, recruiting, retaining and monitoring patients during this part of the cycle is estimated to cost pharma US$19 billion a year as companies seek to harvest patient experiences.

Vaccines 119

Vaccines Hospitals Pharmaceutical Companies Pharmaceutical Companies 119

Pharmaceutical Technology

SEPTEMBER 26, 2022

These highlight the parent company’s focus on innovative and high-value drug development. Sandoz has faced and may in the future face strong competition from other generic and biosimilar pharmaceutical companies, which aggressively compete for market share, including through significant price competition.

Biosimilars 64

Biosimilars Drug Development Vaccines Dosage 64

Putting Patients First Blog

JUNE 30, 2023

have robust suggestions on increasing diversity in clinical trials for sponsors and drug developers. As an organization with a diverse membership of multiple patient advocacy organizations and biotech and pharmaceutical companies, we believe these new changes could lead to confusion and duplicative efforts.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Drug Development 40

Pharmaceutical Technology

MARCH 22, 2023

According to the GlobalData report Contract Injectable Packaging Trends in the Bio/Pharma Industry , more than half (55%) of FDA drug approvals in 2021 were accounted for by injectables. This was higher than the number of approvals in 2019 and 2020. Several drug development trends are driving injectables demand.

Packaging 52

Packaging Compounding Pharmaceutical Companies Pharmaceutical Companies 52

European Pharmaceutical Review

JANUARY 16, 2023

” Tony Cundell: Contract manufacturing organisations (CROs), start-up companies, established pharmaceutical companies and regulatory agencies are having difficulty recruiting and retaining technically-trained personnel.

Vaccines 128

Vaccines Research Laboratories Documentation Compounding 128

Pharmaceutical Technology

FEBRUARY 20, 2023

We are delighted to deepen our partnership with Teddy Lab that will enable us to build on existing knowledge and increase services within China to support customers with their global drug development programmes. Particularly, Teddy Lab Wuxi set up in 2020 with the great help of Wuxi Government. SZ) and Tigermed (300347.SZ

Research Laboratories 52

Research Laboratories Drug Development Vaccines Communication 52

Pharmaceutical Technology

AUGUST 1, 2022

Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. These should be developed alongside worldwide initiatives and collaborative efforts to pool both research and educational resources.

Vaccines 93

Vaccines Pharmaceutical Companies Pharmaceutical Companies Chemotherapy 93

European Pharmaceutical Review

FEBRUARY 3, 2025

In recent years, leading pharmaceutical companies, such as Sanofi, successfully launched smart factory programmes. What lessons can you offer to other manufacturers/drug developers? This technology achieves higher process throughput, low labour cost, increased flexibility and reduced risk.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines Drug Development 52